0	0	1998-09-21	CD	O	O	B-Num
0	1	16	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	20	CD	O	B-NP	I-Num
0	4	BIOTECH	NNP	O	I-NP	B-Org
0	5	LEADER	NN	O	I-NP	I-Org
0	6	PLOWS	NNP	O	I-NP	I-Org
0	7	AHEAD	RB	O	O	I-Org
0	8	UNDER	IN	O	O	I-Org
0	9	NEW	JJ	O	B-NP	I-Org
0	10	LEADERSHIP	NNP	O	I-NP	I-Org

1	0	SAN	NNP	O	O	O
1	1	FRANCISCO	NNP	O	O	O
1	2	_	NN	O	O	O
1	3	Genentech	NNP	O	B-NP	B-Peop
1	4	Inc.	NNP	O	I-NP	I-Peop
1	5	COMMA	COMMA	O	O	O
1	6	a	DT	O	B-NP	O
1	7	trailblazer	NN	O	I-NP	O
1	8	in	IN	O	B-PP	O
1	9	the	DT	O	B-NP	O
1	10	American	JJ	O	I-NP	B-LangRace
1	11	biotechnology	NN	O	I-NP	O
1	12	industry	NN	O	I-NP	O
1	13	COMMA	COMMA	O	O	O
1	14	is	VBZ	O	B-VP	O
1	15	finally	RB	O	I-VP	O
1	16	reaping	VBG	O	I-VP	O
1	17	the	DT	O	B-NP	O
1	18	benefits	NNS	O	I-NP	O
1	19	of	IN	O	B-PP	O
1	20	a	DT	O	B-NP	O
1	21	reorganization	NN	O	I-NP	O
1	22	that	WDT	O	B-NP	O
1	23	began	VBD	O	B-VP	O
1	24	three	CD	O	B-NP	B-Num
1	25	years	NNS	O	I-NP	B-Date
1	26	ago	IN	O	O	O
1	27	.	.	O	O	O

2	0	Last	JJ	O	B-NP	O
2	1	year	NN	O	I-NP	O
2	2	COMMA	COMMA	O	O	O
2	3	the	DT	O	B-NP	O
2	4	South	NNP	O	I-NP	O
2	5	San	NNP	O	I-NP	O
2	6	Francisco-based	JJ	O	I-NP	O
2	7	biotechnology	NN	O	I-NP	O
2	8	company	NN	O	I-NP	B-OrgCorp
2	9	received	VBD	O	B-VP	O
2	10	approval	NN	O	B-NP	O
2	11	to	TO	O	B-VP	O
2	12	market	VB	O	I-VP	O
2	13	Rituxan	NNP	O	B-NP	O
2	14	COMMA	COMMA	O	O	O
2	15	which	WDT	O	B-NP	O
2	16	cures	VBZ	O	B-VP	O
2	17	a	DT	O	B-NP	O
2	18	certain	JJ	O	I-NP	O
2	19	type	NN	O	I-NP	O
2	20	of	IN	O	B-PP	O
2	21	lymphoma	NN	O	B-NP	B-Medical
2	22	and	CC	O	O	O
2	23	took	VBD	O	B-VP	O
2	24	seven	CD	O	B-NP	B-Num
2	25	years	NNS	O	I-NP	B-Date
2	26	to	TO	O	B-VP	O
2	27	develop	VB	O	I-VP	O
2	28	.	.	O	O	O

3	0	So	RB	O	O	O
3	1	far	RB	O	O	O
3	2	COMMA	COMMA	O	O	O
3	3	it	PRP	O	B-NP	O
3	4	has	VBZ	O	B-VP	O
3	5	grossed	VBD	O	I-VP	O
3	6	$78	NN	O	B-NP	B-Money
3	7	million	CD	O	I-NP	B-Num
3	8	in	IN	O	B-PP	O
3	9	sales	NNS	O	B-NP	O
3	10	.	.	O	O	O

4	0	Now	RB	O	O	O
4	1	COMMA	COMMA	O	O	O
4	2	it	PRP	O	B-NP	O
4	3	is	VBZ	O	B-VP	O
4	4	awaiting	VBG	O	I-VP	O
4	5	the	DT	O	B-NP	O
4	6	green	JJ	O	I-NP	B-Color
4	7	light	NN	O	I-NP	O
4	8	for	IN	O	B-PP	O
4	9	its	PP$	O	B-NP	O
4	10	vaunted	JJ	O	I-NP	O
4	11	breast	NN	O	I-NP	O
4	12	cancer	NN	O	I-NP	B-Medical
4	13	drug	NN	O	I-NP	I-Medical
4	14	COMMA	COMMA	O	O	O
4	15	Herceptin	NNP	O	B-NP	B-Loc
4	16	.	.	O	O	O

5	0	The	DT	O	B-NP	O
5	1	Food	NNP	O	I-NP	B-Org
5	2	and	CC	O	I-NP	I-Org
5	3	Drug	NNP	O	I-NP	I-Org
5	4	Administration	NNP	O	I-NP	I-Org
5	5	is	VBZ	O	B-VP	O
5	6	expected	VBN	O	I-VP	O
5	7	to	TO	O	I-VP	O
5	8	approve	VB	O	I-VP	O
5	9	the	DT	O	B-NP	O
5	10	sale	NN	O	I-NP	O
5	11	of	IN	O	B-PP	O
5	12	the	DT	O	B-NP	O
5	13	bioengineered	JJ	O	I-NP	O
5	14	formulation	NN	O	I-NP	O
5	15	by	IN	O	B-PP	O
5	16	December	NNP	O	B-NP	B-Date
5	17	.	.	O	O	O

6	0	And	CC	O	O	O
6	1	Genentech	NNP	O	B-NP	B-OrgCorp
6	2	has	VBZ	O	B-VP	O
6	3	a	DT	O	B-NP	O
6	4	string	NN	O	I-NP	O
6	5	of	IN	O	B-PP	O
6	6	other	JJ	O	B-NP	O
6	7	products	NNS	O	I-NP	O
6	8	in	IN	O	B-PP	O
6	9	late-stage	JJ	O	B-NP	O
6	10	clinical	JJ	O	I-NP	B-Medical
6	11	trials	NNS	O	I-NP	O
6	12	COMMA	COMMA	O	O	O
6	13	including	VBG	O	B-PP	O
6	14	drugs	NNS	O	B-NP	O
6	15	that	IN	O	B-NP	O
6	16	cure	VBP	O	B-VP	O
6	17	allergies	NNS	O	B-NP	O
6	18	and	CC	O	I-NP	O
6	19	asthma	NN	O	I-NP	B-Medical
6	20	COMMA	COMMA	O	O	O
6	21	and	CC	O	O	O
6	22	treat	VBP	O	B-VP	O
6	23	nerve	NN	O	B-NP	O
6	24	damage	NN	O	I-NP	O
6	25	caused	VBN	O	B-VP	O
6	26	by	IN	O	B-PP	O
6	27	diabetes	NN	O	B-NP	B-Medical
6	28	.	.	O	O	O

7	0	``	``	O	O	O
7	1	It	PRP	O	B-NP	O
7	2	's	VBZ	O	B-VP	O
7	3	an	DT	O	B-NP	O
7	4	amazing	JJ	O	I-NP	O
7	5	turnaround	NN	O	I-NP	O
7	6	storyCOMMA	NN	O	I-NP	O
7	7	''	''	O	O	O
7	8	said	VBD	O	B-VP	O
7	9	Meirav	NNP	O	B-NP	B-Peop
7	10	Chovav	NNP	O	I-NP	I-Peop
7	11	COMMA	COMMA	O	O	O
7	12	an	DT	O	B-NP	O
7	13	analyst	NN	O	I-NP	B-ProfTitle
7	14	at	IN	O	B-PP	O
7	15	Salomon	NNP	O	B-NP	B-Peop
7	16	Smith	NNP	O	I-NP	B-Peop
7	17	Barney	NNP	O	I-NP	I-Peop
7	18	in	IN	O	B-PP	O
7	19	New	NNP	O	B-NP	B-LocCit
7	20	York	NNP	O	I-NP	I-LocCit
7	21	.	.	O	O	O

8	0	In	IN	O	B-PP	O
8	1	the	DT	O	B-NP	O
8	2	early	JJ	O	I-NP	O
8	3	1990s	CD	O	I-NP	B-Date
8	4	COMMA	COMMA	O	O	O
8	5	Genentech	NNP	O	B-NP	B-OrgCorp
8	6	had	VBD	O	B-VP	O
8	7	been	VBN	O	I-VP	O
8	8	mired	VBN	O	I-VP	O
8	9	by	IN	O	B-PP	O
8	10	controversial	JJ	O	B-NP	O
8	11	marketing	NN	O	I-NP	O
8	12	tactics	NNS	O	I-NP	O
8	13	and	CC	O	O	O
8	14	a	DT	O	B-NP	O
8	15	questionable	JJ	O	I-NP	O
8	16	financial	JJ	O	I-NP	O
8	17	arrangement	NN	O	I-NP	O
8	18	pursued	VBD	O	B-VP	O
8	19	by	IN	O	B-PP	O
8	20	then-chief	JJ	O	B-NP	O
8	21	executive	JJ	O	I-NP	B-ProfTitle
8	22	G.	NNP	O	I-NP	B-OrgCorp
8	23	Kirk	NNP	O	I-NP	B-Peop
8	24	Raab	NNP	O	I-NP	I-Peop
8	25	.	.	O	O	O

9	0	Both	DT	O	B-NP	O
9	1	situations	NNS	O	I-NP	O
9	2	detracted	VBN	O	B-VP	O
9	3	from	IN	O	B-PP	O
9	4	Genentech	NNP	O	B-NP	B-OrgCorp
9	5	's	POS	O	B-NP	O
9	6	ability	NN	O	I-NP	O
9	7	to	TO	O	B-PP	O
9	8	roll-out	NN	O	B-NP	O
9	9	new	JJ	O	I-NP	O
9	10	drugs	NNS	O	I-NP	O
9	11	COMMA	COMMA	O	O	O
9	12	analysts	NNS	O	B-NP	B-ProfTitle
9	13	said	VBD	O	B-VP	O
9	14	.	.	O	O	O

10	0	Financially	RB	O	O	O
10	1	COMMA	COMMA	O	O	O
10	2	however	RB	O	O	O
10	3	COMMA	COMMA	O	O	O
10	4	Genentech	NNP	O	B-NP	B-OrgCorp
10	5	has	VBZ	O	B-VP	O
10	6	been	VBN	O	I-VP	O
10	7	humming	VBG	O	I-VP	O
10	8	along	IN	O	O	O
10	9	thanks	NNS	O	B-NP	O
10	10	to	TO	O	B-PP	O
10	11	a	DT	O	B-NP	O
10	12	$2.1	NN	O	I-NP	B-Money
10	13	billion	CD	O	I-NP	B-Num
10	14	investment	NN	O	I-NP	O
10	15	from	IN	O	B-PP	O
10	16	Swiss	JJ	O	B-NP	O
10	17	drug	NN	O	I-NP	B-Medical
10	18	giant	NN	O	I-NP	O
10	19	Roche	NNP	O	I-NP	O
10	20	Holding	NNP	O	I-NP	O
10	21	Ltd.	NNP	O	I-NP	O
10	22	in	IN	O	B-PP	O
10	23	1990	CD	O	B-NP	B-Date
10	24	.	.	O	O	O

11	0	The	DT	O	B-NP	O
11	1	investment	NN	O	I-NP	O
11	2	_	NN	O	I-NP	O
11	3	which	WDT	O	B-NP	O
11	4	included	VBD	O	B-VP	O
11	5	about	IN	O	O	O
11	6	$500	NN	O	B-NP	B-Money
11	7	million	CD	O	I-NP	B-Num
11	8	in	IN	O	B-PP	O
11	9	cash	NN	O	B-NP	O
11	10	earmarked	VBN	O	B-VP	O
11	11	for	IN	O	B-PP	O
11	12	research	NN	O	B-NP	O
11	13	to	TO	O	B-VP	O
11	14	maintain	VB	O	I-VP	O
11	15	the	DT	O	B-NP	O
11	16	company	NN	O	I-NP	B-OrgCorp
11	17	's	POS	O	B-NP	O
11	18	long-term	JJ	O	I-NP	O
11	19	product	NN	O	I-NP	O
11	20	pipeline	NN	O	I-NP	O
11	21	_	NN	O	I-NP	O
11	22	resulted	VBD	O	B-VP	O
11	23	in	IN	O	B-PP	O
11	24	Roche	NNP	O	B-NP	B-Loc
11	25	acquiring	VBG	O	B-VP	O
11	26	66	CD	O	B-NP	B-NumPercent
11	27	percent	NN	O	I-NP	I-NumPercent
11	28	of	IN	O	B-PP	O
11	29	Genentech	NNP	O	B-NP	B-OrgCorp
11	30	.	.	O	O	O

12	0	Today	NN	O	B-NP	B-Date
12	1	COMMA	COMMA	O	O	O
12	2	Genentech	NNP	O	B-NP	B-OrgCorp
12	3	's	POS	O	B-NP	O
12	4	revenues	NNS	O	I-NP	O
12	5	are	VBP	O	B-VP	O
12	6	robust	JJ	O	O	O
12	7	COMMA	COMMA	O	O	O
12	8	analysts	NNS	O	B-NP	B-ProfTitle
12	9	said	VBD	O	B-VP	O
12	10	.	.	O	O	O

13	0	Last	JJ	O	B-NP	O
13	1	year	NN	O	I-NP	O
13	2	COMMA	COMMA	O	O	O
13	3	the	DT	O	B-NP	O
13	4	company	NN	O	I-NP	B-OrgCorp
13	5	passed	VBD	O	B-VP	O
13	6	the	DT	O	B-NP	O
13	7	$1	NN	O	I-NP	B-Money
13	8	billion	CD	O	I-NP	B-Num
13	9	sales	NNS	O	I-NP	O
13	10	mark	VBP	O	B-VP	B-Money
13	11	.	.	O	O	O

14	0	And	CC	O	O	O
14	1	net	JJ	O	B-NP	O
14	2	income	NN	O	I-NP	O
14	3	was	VBD	O	B-VP	O
14	4	$129	NN	O	B-NP	B-Money
14	5	million	CD	O	I-NP	B-Num
14	6	in	IN	O	B-PP	O
14	7	1997	CD	O	B-NP	B-Date
14	8	.	.	O	O	O

15	0	In	IN	O	B-PP	O
15	1	a	DT	O	B-NP	O
15	2	recent	JJ	O	I-NP	O
15	3	interview	NN	O	I-NP	O
15	4	at	IN	O	B-PP	O
15	5	Genentech	NNP	O	B-NP	B-OrgCorp
15	6	's	POS	O	B-NP	O
15	7	sprawling	VBG	O	I-NP	O
15	8	COMMA	COMMA	O	I-NP	O
15	9	maze-like	JJ	O	I-NP	O
15	10	campus	NN	O	I-NP	O
15	11	at	IN	O	B-PP	O
15	12	One	CD	O	B-NP	B-Num
15	13	DNA	NN	O	I-NP	O
15	14	Way	NNP	O	I-NP	B-Peop
15	15	COMMA	COMMA	O	O	O
15	16	the	DT	O	B-NP	O
15	17	chief	NN	O	I-NP	B-ProfTitle
15	18	financial	JJ	O	I-NP	O
15	19	officer	NN	O	I-NP	B-ProfTitle
15	20	COMMA	COMMA	O	O	O
15	21	Louis	NNP	O	B-NP	B-Peop
15	22	J.	NNP	O	I-NP	I-Peop
15	23	Lavigne	NNP	O	I-NP	I-Peop
15	24	said	VBD	O	B-VP	O
15	25	that	IN	O	O	O
15	26	in	IN	O	B-PP	O
15	27	the	DT	O	B-NP	O
15	28	next	JJ	O	I-NP	O
15	29	millennium	NN	O	I-NP	O
15	30	he	PRP	O	B-NP	O
15	31	expects	VBZ	O	B-VP	O
15	32	his	PP$	O	B-NP	O
15	33	company	NN	O	I-NP	B-OrgCorp
15	34	's	POS	O	B-NP	O
15	35	sales	NNS	O	I-NP	O
15	36	to	TO	O	B-VP	O
15	37	grow	VB	O	I-VP	O
15	38	20	CD	O	B-NP	B-NumPercent
15	39	percent	NN	O	I-NP	I-NumPercent
15	40	to	TO	O	B-PP	O
15	41	30	CD	O	B-NP	B-NumPercent
15	42	percent	NN	O	I-NP	I-NumPercent
15	43	a	DT	O	B-NP	O
15	44	year	NN	O	I-NP	O
15	45	.	.	O	O	O

16	0	Profits	NNS	O	B-NP	O
16	1	COMMA	COMMA	O	O	O
16	2	he	PRP	O	B-NP	O
16	3	added	VBD	O	B-VP	O
16	4	COMMA	COMMA	O	O	O
16	5	should	MD	O	B-VP	O
16	6	rise	VB	O	I-VP	O
16	7	to	TO	O	B-PP	O
16	8	at	IN	O	B-NP	O
16	9	least	JJS	O	I-NP	O
16	10	25	CD	O	I-NP	B-NumPercent
16	11	percent	NN	O	I-NP	I-NumPercent
16	12	of	IN	O	B-PP	O
16	13	sales	NNS	O	B-NP	O
16	14	.	.	O	O	O

17	0	``	``	O	O	O
17	1	This	DT	O	B-NP	O
17	2	is	VBZ	O	B-VP	O
17	3	one	CD	O	B-NP	B-Num
17	4	of	IN	O	B-PP	O
17	5	the	DT	O	B-NP	O
17	6	most	RBS	O	I-NP	O
17	7	exciting	JJ	O	I-NP	O
17	8	times	NNS	O	I-NP	O
17	9	in	IN	O	B-PP	O
17	10	the	DT	O	B-NP	O
17	11	company	NN	O	I-NP	B-OrgCorp
17	12	COMMA	COMMA	O	O	O
17	13	and	CC	O	O	O
17	14	the	DT	O	B-NP	O
17	15	reason	NN	O	I-NP	O
17	16	for	IN	O	B-PP	O
17	17	that	DT	O	B-NP	O
17	18	is	VBZ	O	B-VP	O
17	19	seeing	VBG	O	I-VP	O
17	20	the	DT	O	B-NP	O
17	21	pipeline	NN	O	I-NP	O
17	22	moving	VBG	O	B-VP	O
17	23	forward	RB	O	O	O
17	24	and	CC	O	O	O
17	25	recognizing	VBG	O	B-VP	O
17	26	the	DT	O	B-NP	O
17	27	potential	NN	O	I-NP	O
17	28	that	IN	O	B-NP	O
17	29	it	PRP	O	B-NP	O
17	30	has	VBZ	O	B-VP	O
17	31	for	IN	O	B-PP	O
17	32	meeting	VBG	O	B-VP	O
17	33	the	DT	O	B-NP	O
17	34	various	JJ	O	I-NP	O
17	35	unmet	JJ	O	I-NP	O
17	36	needs	NNS	O	I-NP	O
17	37	of	IN	O	B-PP	O
17	38	patientsCOMMA	NN	O	B-NP	O
17	39	''	''	O	O	O
17	40	Lavigne	NNP	O	B-NP	B-Peop
17	41	said	VBD	O	B-VP	O
17	42	.	.	O	O	O

18	0	Once	RB	O	O	O
18	1	a	DT	O	B-NP	O
18	2	Genentech	NNP	O	I-NP	B-OrgCorp
18	3	scientist	NN	O	I-NP	B-ProfTitle
18	4	makes	VBZ	O	B-VP	O
18	5	a	DT	O	B-NP	O
18	6	discovery	NN	O	I-NP	O
18	7	in	IN	O	B-PP	O
18	8	the	DT	O	B-NP	O
18	9	lab	NN	O	I-NP	O
18	10	COMMA	COMMA	O	O	O
18	11	pre-clinical	JJ	O	B-NP	O
18	12	tests	NNS	O	I-NP	O
18	13	are	VBP	O	B-VP	O
18	14	conducted	VBN	O	I-VP	O
18	15	to	TO	O	I-VP	O
18	16	determine	VB	O	I-VP	O
18	17	whether	IN	O	O	O
18	18	the	DT	O	B-NP	O
18	19	discovery	NN	O	I-NP	O
18	20	is	VBZ	O	B-VP	O
18	21	suitable	JJ	O	O	O
18	22	for	IN	O	B-PP	O
18	23	humans	NNS	O	B-NP	O
18	24	.	.	O	O	O

19	0	If	IN	O	O	O
19	1	it	PRP	O	B-NP	O
19	2	is	VBZ	O	B-VP	O
19	3	COMMA	COMMA	O	O	O
19	4	the	DT	O	B-NP	O
19	5	product	NN	O	I-NP	O
19	6	goes	VBZ	O	B-VP	O
19	7	into	IN	O	B-PP	O
19	8	the	DT	O	B-NP	O
19	9	first	JJ	O	I-NP	B-Num
19	10	of	IN	O	B-PP	O
19	11	three	CD	O	B-NP	B-Num
19	12	clinical	JJ	O	I-NP	B-Medical
19	13	trials	NNS	O	I-NP	O
19	14	.	.	O	O	O

20	0	After	IN	O	B-PP	O
20	1	the	DT	O	B-NP	O
20	2	drug	NN	O	I-NP	B-Medical
20	3	passes	VBZ	O	B-VP	O
20	4	the	DT	O	B-NP	O
20	5	last	JJ	O	I-NP	O
20	6	trial	NN	O	I-NP	O
20	7	COMMA	COMMA	O	O	O
20	8	the	DT	O	B-NP	O
20	9	company	NN	O	I-NP	B-OrgCorp
20	10	takes	VBZ	O	B-VP	O
20	11	its	PP$	O	B-NP	O
20	12	results	NNS	O	I-NP	O
20	13	to	TO	O	B-PP	O
20	14	the	DT	O	B-NP	O
20	15	FDA	NNP	O	I-NP	B-Org
20	16	COMMA	COMMA	O	O	O
20	17	which	WDT	O	B-NP	O
20	18	must	MD	O	B-VP	O
20	19	approve	VB	O	I-VP	O
20	20	it	PRP	O	B-NP	O
20	21	.	.	O	O	O

21	0	Genentech	NNP	O	B-NP	B-OrgCorp
21	1	spokeswoman	NN	O	I-NP	O
21	2	Laura	NNP	O	I-NP	B-Peop
21	3	Leber	NNP	O	I-NP	I-Peop
21	4	said	VBD	O	B-VP	O
21	5	the	DT	O	B-NP	O
21	6	time	NN	O	I-NP	O
21	7	it	PRP	O	B-NP	O
21	8	takes	VBZ	O	B-VP	O
21	9	new	JJ	O	B-NP	O
21	10	drugs	NNS	O	I-NP	O
21	11	to	TO	O	B-VP	O
21	12	go	VB	O	I-VP	O
21	13	from	IN	O	B-PP	O
21	14	the	DT	O	B-NP	O
21	15	research	NN	O	I-NP	O
21	16	stage	NN	O	I-NP	O
21	17	to	TO	O	B-PP	O
21	18	market	NN	O	B-NP	O
21	19	is	VBZ	O	B-VP	O
21	20	about	IN	O	B-NP	O
21	21	10	CD	O	I-NP	B-Num
21	22	to	TO	O	I-NP	O
21	23	12	CD	O	I-NP	B-Num
21	24	years	NNS	O	I-NP	I-Num
21	25	on	IN	O	B-PP	O
21	26	average	NN	O	B-NP	O
21	27	for	IN	O	B-PP	O
21	28	the	DT	O	B-NP	O
21	29	industry	NN	O	I-NP	O
21	30	.	.	O	O	O

22	0	The	DT	O	B-NP	O
22	1	cost	NN	O	I-NP	O
22	2	of	IN	O	B-PP	O
22	3	developing	VBG	O	B-VP	O
22	4	a	DT	O	B-NP	O
22	5	new	JJ	O	I-NP	O
22	6	drug	NN	O	I-NP	B-Medical
22	7	COMMA	COMMA	O	O	O
22	8	she	PRP	O	B-NP	O
22	9	said	VBD	O	B-VP	O
22	10	COMMA	COMMA	O	O	O
22	11	can	MD	O	B-VP	O
22	12	run	VB	O	I-VP	O
22	13	into	IN	O	B-PP	O
22	14	the	DT	O	B-NP	O
22	15	hundreds	NNS	O	I-NP	B-Num
22	16	of	IN	O	B-PP	O
22	17	millions	NNS	O	B-NP	B-Num
22	18	of	IN	O	B-PP	O
22	19	dollars	NNS	O	B-NP	B-Money
22	20	.	.	O	O	O

23	0	Genentech	NNP	O	B-NP	B-OrgCorp
23	1	was	VBD	O	B-VP	O
23	2	founded	VBN	O	I-VP	O
23	3	in	IN	O	B-PP	O
23	4	1976	CD	O	B-NP	B-Date
23	5	by	IN	O	B-PP	O
23	6	venture	NN	O	B-NP	O
23	7	capitalist	JJ	O	I-NP	B-OrgPolBody
23	8	Robert	NNP	O	I-NP	B-Peop
23	9	Swanson	NNP	O	I-NP	I-Peop
23	10	and	CC	O	O	O
23	11	molecular	JJ	O	B-NP	B-Medical
23	12	biologist	NN	O	I-NP	B-ProfTitle
23	13	Herbert	NNP	O	I-NP	B-Peop
23	14	Boyer	NNP	O	I-NP	I-Peop
23	15	to	TO	O	B-VP	O
23	16	commercialize	VB	O	I-VP	O
23	17	genetically	RB	O	B-NP	O
23	18	engineered	VBN	O	I-NP	O
23	19	products	NNS	O	I-NP	O
23	20	.	.	O	O	O

24	0	Boyer	NNP	O	B-NP	B-Peop
24	1	held	VBD	O	B-VP	O
24	2	a	DT	O	B-NP	O
24	3	patent	NN	O	I-NP	O
24	4	on	IN	O	B-PP	O
24	5	techniques	NNS	O	B-NP	O
24	6	for	IN	O	B-PP	O
24	7	splicing	VBG	O	O	O
24	8	genes	NNS	O	B-NP	O
24	9	into	IN	O	B-PP	O
24	10	micro-organisms	NNS	O	B-NP	O
24	11	that	WDT	O	B-NP	O
24	12	could	MD	O	B-VP	O
24	13	be	VB	O	I-VP	O
24	14	used	VBN	O	I-VP	O
24	15	as	IN	O	B-PP	O
24	16	``	``	O	O	O
24	17	microfactories	NNS	O	B-NP	O
24	18	''	''	O	O	O
24	19	to	TO	O	B-VP	O
24	20	produce	VB	O	I-VP	O
24	21	large	JJ	O	B-NP	O
24	22	amounts	NNS	O	I-NP	O
24	23	of	IN	O	B-PP	O
24	24	therapeutic	JJ	O	B-NP	B-Medical
24	25	substances	NNS	O	I-NP	O
24	26	.	.	O	O	O

25	0	``	``	O	O	O
25	1	Bob	NNP	O	B-NP	B-Peop
25	2	Swanson	NNP	O	I-NP	I-Peop
25	3	took	VBD	O	B-VP	O
25	4	the	DT	O	B-NP	O
25	5	entrepreneurial	JJ	O	I-NP	O
25	6	lessons	NNS	O	I-NP	O
25	7	he	PRP	O	B-NP	O
25	8	learned	VBD	O	B-VP	O
25	9	from	IN	O	B-PP	O
25	10	Silicon	NNP	O	B-NP	B-LocCit
25	11	Valley	NNP	O	I-NP	I-LocCit
25	12	and	CC	O	O	O
25	13	applied	VBD	O	B-VP	O
25	14	them	PRP	O	B-NP	O
25	15	to	TO	O	B-PP	O
25	16	biology	NN	O	B-NP	O
25	17	companiesCOMMA	NN	O	I-NP	O
25	18	''	''	O	O	O
25	19	said	VBD	O	B-VP	O
25	20	Cynthia	NNP	O	B-NP	B-Peop
25	21	Robbins-Roth	NNP	O	I-NP	I-Peop
25	22	COMMA	COMMA	O	O	O
25	23	a	DT	O	B-NP	O
25	24	former	JJ	O	I-NP	O
25	25	Genentech	NNP	O	I-NP	B-OrgCorp
25	26	researcher	NN	O	I-NP	B-ProfTitle
25	27	and	CC	O	O	O
25	28	now	RB	O	O	O
25	29	editor	NN	O	B-NP	B-ProfTitle
25	30	of	IN	O	B-PP	O
25	31	BioVenture	NNP	O	B-NP	O
25	32	View	NNP	O	I-NP	O
25	33	COMMA	COMMA	O	O	O
25	34	a	DT	O	B-NP	O
25	35	trade	VBP	O	I-NP	O
25	36	newsletter	NN	O	I-NP	O
25	37	base	NN	O	I-NP	O
25	38	in	IN	O	B-PP	O
25	39	San	NNP	O	B-NP	B-LocCit
25	40	Mateo	NNP	O	I-NP	I-LocCit
25	41	.	.	O	O	O

26	0	``	``	O	O	O
26	1	That	DT	O	B-NP	O
26	2	model	NN	O	I-NP	B-ProfTitle
26	3	-LBR-	-LBR-	O	O	O
26	4	Genentech	NNP	O	O	B-OrgCorp
26	5	-RBR-	-RBR-	O	O	O
26	6	has	VBZ	O	B-VP	O
26	7	successfully	RB	O	I-VP	O
26	8	created	VBN	O	I-VP	O
26	9	an	DT	O	B-NP	O
26	10	industry	NN	O	I-NP	O
26	11	with	IN	O	B-PP	O
26	12	300-plus	NN	O	B-NP	B-Num
26	13	companiesCOMMA	NN	O	I-NP	O
26	14	''	''	O	O	O
26	15	she	PRP	O	B-NP	O
26	16	added	VBD	O	B-VP	O
26	17	.	.	O	O	O

27	0	Industry	NN	O	B-NP	O
27	1	watchers	NNS	O	I-NP	O
27	2	said	VBD	O	B-VP	O
27	3	Genentech	NNP	O	B-NP	B-OrgCorp
27	4	's	POS	O	B-NP	O
27	5	latest	JJS	O	I-NP	O
27	6	upward	JJ	O	I-NP	O
27	7	trend	NN	O	I-NP	O
27	8	began	VBD	O	B-VP	O
27	9	with	IN	O	B-PP	O
27	10	the	DT	O	B-NP	O
27	11	ouster	NN	O	I-NP	O
27	12	of	IN	O	B-PP	O
27	13	Raab	NNP	O	B-NP	O
27	14	in	IN	O	B-PP	O
27	15	1995	CD	O	B-NP	B-Date
27	16	and	CC	O	O	O
27	17	the	DT	O	B-NP	O
27	18	promotion	NN	O	I-NP	O
27	19	of	IN	O	B-PP	O
27	20	Dr.	NNP	O	B-NP	B-ProfTitle
27	21	Arthur	NNP	O	I-NP	B-Peop
27	22	Levinson	NNP	O	I-NP	I-Peop
27	23	to	TO	O	B-PP	O
27	24	chief	NN	O	B-NP	B-ProfTitle
27	25	executive	NN	O	I-NP	B-ProfTitle
27	26	.	.	O	O	O

28	0	Raab	NNP	O	B-NP	B-Peop
28	1	COMMA	COMMA	O	O	O
28	2	who	WP	O	B-NP	O
28	3	had	VBD	O	B-VP	O
28	4	been	VBN	O	I-VP	O
28	5	appointed	VBN	O	I-VP	O
28	6	chief	NN	O	B-NP	B-ProfTitle
28	7	executive	NN	O	I-NP	B-ProfTitle
28	8	in	IN	O	B-PP	O
28	9	1990	CD	O	B-NP	B-Date
28	10	COMMA	COMMA	O	O	O
28	11	was	VBD	O	B-VP	O
28	12	fired	VBN	O	I-VP	O
28	13	by	IN	O	B-PP	O
28	14	the	DT	O	B-NP	O
28	15	Genentech	NNP	O	I-NP	B-OrgCorp
28	16	board	NN	O	I-NP	O
28	17	after	IN	O	B-PP	O
28	18	trying	VBG	O	B-VP	O
28	19	to	TO	O	I-VP	O
28	20	secure	VB	O	I-VP	O
28	21	a	DT	O	B-NP	O
28	22	$2	NN	O	I-NP	B-Money
28	23	million	CD	O	I-NP	B-Num
28	24	personal	JJ	O	I-NP	O
28	25	loan	NN	O	I-NP	O
28	26	guarantee	NN	O	I-NP	O
28	27	from	IN	O	B-PP	O
28	28	Roche	NNP	O	B-NP	B-Peop
28	29	.	.	O	O	O

29	0	At	IN	O	B-PP	O
29	1	the	DT	O	B-NP	O
29	2	same	JJ	O	I-NP	O
29	3	time	NN	O	I-NP	O
29	4	he	PRP	O	B-NP	O
29	5	was	VBD	O	B-VP	O
29	6	negotiating	VBG	O	I-VP	O
29	7	a	DT	O	B-NP	O
29	8	personal	JJ	O	I-NP	O
29	9	loan	NN	O	I-NP	O
29	10	COMMA	COMMA	O	O	O
29	11	Raab	NNP	O	B-NP	B-Peop
29	12	was	VBD	O	B-VP	O
29	13	in	IN	O	B-PP	O
29	14	the	DT	O	B-NP	O
29	15	midst	NN	O	I-NP	O
29	16	of	IN	O	B-PP	O
29	17	hashing	VBG	O	B-VP	O
29	18	out	IN	O	O	O
29	19	a	DT	O	B-NP	O
29	20	new	JJ	O	I-NP	O
29	21	financial	JJ	O	I-NP	O
29	22	arrangement	NN	O	I-NP	O
29	23	with	IN	O	B-PP	O
29	24	the	DT	O	B-NP	O
29	25	Swiss	JJ	O	I-NP	O
29	26	drug	NN	O	I-NP	B-Medical
29	27	maker	NN	O	I-NP	O
29	28	_	NN	O	O	O
29	29	one	CD	O	B-NP	B-Num
29	30	that	WDT	O	B-NP	O
29	31	gives	VBZ	O	B-VP	O
29	32	Roche	NNP	O	B-NP	B-Peop
29	33	the	DT	O	B-NP	O
29	34	option	NN	O	I-NP	O
29	35	to	TO	O	B-VP	O
29	36	buy	VB	O	I-VP	O
29	37	the	DT	O	B-NP	O
29	38	rest	NN	O	I-NP	O
29	39	of	IN	O	B-PP	O
29	40	Genentech	NNP	O	B-NP	B-OrgCorp
29	41	by	IN	O	B-PP	O
29	42	July	NNP	O	B-NP	B-Date
29	43	1999	CD	O	I-NP	I-Date
29	44	if	IN	O	O	O
29	45	Genentech	NNP	O	B-NP	B-Peop
29	46	's	POS	O	B-NP	O
29	47	stock	NN	O	I-NP	O
29	48	falls	VBZ	O	B-VP	O
29	49	below	IN	O	B-PP	O
29	50	$60	NN	O	B-NP	B-Money
29	51	per	IN	O	B-PP	O
29	52	share	VBP	O	B-NP	O
29	53	at	IN	O	B-PP	O
29	54	that	DT	O	B-NP	O
29	55	time	NN	O	I-NP	O
29	56	.	.	O	O	O

30	0	Raab	NNP	O	B-NP	B-Peop
30	1	said	VBD	O	B-VP	O
30	2	he	PRP	O	B-NP	O
30	3	``	``	O	O	O
30	4	never	RB	O	O	O
30	5	took	VBD	O	B-VP	O
30	6	that	DT	O	B-NP	O
30	7	loan	NN	O	I-NP	O
30	8	.	.	O	O	O

31	0	But	CC	O	O	O
31	1	I	PRP	O	B-NP	O
31	2	did	VBD	O	B-VP	O
31	3	something	NN	O	B-NP	O
31	4	very	RB	O	O	O
31	5	foolish	JJ	O	O	O
31	6	.	.	O	O	O

32	0	It	PRP	O	B-NP	O
32	1	was	VBD	O	B-VP	O
32	2	inappropriate	JJ	O	O	O
32	3	.	.	O	O	O
32	4	''	''	O	O	O

33	0	Analysts	NNS	O	B-NP	B-Peop
33	1	said	VBD	O	B-VP	O
33	2	the	DT	O	B-NP	O
33	3	discussed	VBN	O	I-NP	O
33	4	loan	NN	O	I-NP	O
33	5	from	IN	O	B-PP	O
33	6	Roche	NNP	O	B-NP	B-Peop
33	7	may	MD	O	B-VP	O
33	8	have	VB	O	I-VP	O
33	9	been	VBN	O	I-VP	O
33	10	the	DT	O	B-NP	O
33	11	last	JJ	O	I-NP	O
33	12	straw	NN	O	I-NP	O
33	13	for	IN	O	B-PP	O
33	14	Raab	NNP	O	B-NP	B-Peop
33	15	COMMA	COMMA	O	O	O
33	16	who	WP	O	B-NP	O
33	17	had	VBD	O	B-VP	O
33	18	previously	RB	O	I-VP	O
33	19	spearheaded	VBD	O	I-VP	O
33	20	a	DT	O	B-NP	O
33	21	controversial	JJ	O	I-NP	O
33	22	marketing	NN	O	I-NP	O
33	23	campaign	NN	O	I-NP	O
33	24	for	IN	O	B-PP	O
33	25	Genentech	NNP	O	B-NP	B-OrgCorp
33	26	's	POS	O	B-NP	O
33	27	human	JJ	O	I-NP	B-Animal
33	28	growth	NN	O	I-NP	B-Medical
33	29	hormone	NN	O	I-NP	I-Medical
33	30	drug	NN	O	I-NP	B-Medical
33	31	COMMA	COMMA	O	O	O
33	32	Protropin	NNP	O	B-NP	B-Peop
33	33	COMMA	COMMA	O	O	O
33	34	that	IN	O	O	O
33	35	combats	NNS	O	B-NP	O
33	36	dwarfism	NN	O	I-NP	O
33	37	.	.	O	O	O

34	0	Essentially	RB	O	O	O
34	1	COMMA	COMMA	O	O	O
34	2	Genentech	NNP	O	B-NP	B-OrgCorp
34	3	was	VBD	O	B-VP	O
34	4	accused	VBN	O	I-VP	O
34	5	of	IN	O	B-PP	O
34	6	pushing	VBG	O	B-VP	O
34	7	the	DT	O	B-NP	O
34	8	drug	NN	O	I-NP	B-Medical
34	9	to	TO	O	B-PP	O
34	10	parents	NNS	O	B-NP	O
34	11	of	IN	O	B-PP	O
34	12	children	NNS	O	B-NP	O
34	13	considered	VBD	O	B-VP	O
34	14	small	JJ	O	O	O
34	15	for	IN	O	B-PP	O
34	16	their	PP$	O	B-NP	O
34	17	age	NN	O	I-NP	O
34	18	but	CC	O	O	O
34	19	still	RB	O	O	O
34	20	normal	JJ	O	B-NP	O
34	21	size	NN	O	I-NP	O
34	22	.	.	O	O	O

35	0	The	DT	O	B-NP	O
35	1	company	NN	O	I-NP	B-OrgCorp
35	2	was	VBD	O	B-VP	O
35	3	later	RB	O	I-VP	O
35	4	sued	VBN	O	I-VP	O
35	5	for	IN	O	B-PP	O
35	6	allegedly	RB	O	O	O
35	7	paying	VBG	O	B-VP	O
35	8	$1	NN	O	B-NP	B-Money
35	9	million	CD	O	I-NP	B-Num
35	10	to	TO	O	B-PP	O
35	11	a	DT	O	B-NP	O
35	12	Minneapolis	NNP	O	I-NP	B-LocCit
35	13	doctor	NN	O	I-NP	B-ProfTitle
35	14	for	IN	O	B-PP	O
35	15	pushing	VBG	O	B-VP	O
35	16	the	DT	O	B-NP	O
35	17	use	NN	O	I-NP	O
35	18	of	IN	O	B-PP	O
35	19	Protropin	NNP	O	B-NP	O
35	20	.	.	O	O	O

36	0	Raab	NNP	O	B-NP	B-Peop
36	1	defended	VBD	O	B-VP	O
36	2	his	PP$	O	B-NP	O
36	3	decisions	NNS	O	I-NP	O
36	4	.	.	O	O	O

37	0	``	``	O	O	O
37	1	I	PRP	O	B-NP	O
37	2	think	VBP	O	B-VP	O
37	3	what	WP	O	B-NP	O
37	4	Genentech	NNP	O	B-NP	B-Peop
37	5	did	VBD	O	B-VP	O
37	6	was	VBD	O	B-VP	O
37	7	wonderful	JJ	O	O	O
37	8	in	IN	O	B-PP	O
37	9	terms	NNS	O	B-NP	O
37	10	of	IN	O	B-PP	O
37	11	the	DT	O	B-NP	O
37	12	marketingCOMMA	NN	O	I-NP	O
37	13	''	''	O	O	O
37	14	he	PRP	O	B-NP	O
37	15	said	VBD	O	B-VP	O
37	16	.	.	O	O	O

38	0	``	``	O	O	O
38	1	I	PRP	O	B-NP	O
38	2	've	VBP	O	B-VP	O
38	3	seen	VBN	O	I-VP	O
38	4	all	DT	O	B-NP	O
38	5	sorts	NNS	O	I-NP	O
38	6	of	IN	O	B-PP	O
38	7	children	NNS	O	B-NP	O
38	8	who	WP	O	B-NP	O
38	9	've	VBP	O	B-VP	O
38	10	gotten	VBN	O	I-VP	O
38	11	it	PRP	O	B-NP	O
38	12	COMMA	COMMA	O	O	O
38	13	and	CC	O	O	O
38	14	instead	RB	O	B-PP	O
38	15	of	IN	O	I-PP	O
38	16	being	VBG	O	B-VP	O
38	17	4-feet-10-inches	JJ	O	O	B-Num
38	18	COMMA	COMMA	O	O	O
38	19	they	PRP	O	B-NP	O
38	20	are	VBP	O	B-VP	O
38	21	five-feet-four	JJ	O	O	O
38	22	.	.	O	O	O
38	23	''	''	O	O	O

39	0	Raab	NNP	O	B-NP	B-Peop
39	1	is	VBZ	O	B-VP	O
39	2	now	RB	O	O	O
39	3	on	IN	O	B-PP	O
39	4	the	DT	O	B-NP	O
39	5	boards	NNS	O	I-NP	O
39	6	of	IN	O	B-PP	O
39	7	four	CD	O	B-NP	B-Num
39	8	biotechnology	NN	O	I-NP	O
39	9	companies	NNS	O	I-NP	B-OrgCorp
39	10	:	:	O	O	O
39	11	Shaman	NNP	O	B-NP	O
39	12	Pharmaceuticals	NNP	O	I-NP	O
39	13	Inc.	NNP	O	I-NP	O
39	14	COMMA	COMMA	O	O	O
39	15	LXR	NNP	O	B-NP	O
39	16	Biotechnology	NNP	O	I-NP	O
39	17	Corp.	NNP	O	I-NP	B-OrgCorp
39	18	and	CC	O	O	O
39	19	Connetics	NNP	O	B-NP	B-OrgCorp
39	20	Corp.	NNP	O	I-NP	I-OrgCorp
39	21	COMMA	COMMA	O	O	O
39	22	all	DT	O	B-NP	O
39	23	in	IN	O	B-PP	O
39	24	California	NNP	O	B-NP	B-LocStat
39	25	;	:	O	O	O
39	26	and	CC	O	O	O
39	27	Oxford	NNP	O	B-NP	B-Org
39	28	Glycosciences	NNP	O	I-NP	I-Org
39	29	Ltd.	NNP	O	I-NP	I-Org
39	30	in	IN	O	B-PP	O
39	31	Oxford	NNP	O	B-NP	B-Loc
39	32	COMMA	COMMA	O	O	O
39	33	England	NNP	O	B-NP	B-Loc
39	34	.	.	O	O	O

40	0	Levinson	NNP	O	O	B-Peop
40	1	COMMA	COMMA	O	O	O
40	2	who	WP	O	B-NP	O
40	3	had	VBD	O	B-VP	O
40	4	been	VBN	O	I-VP	O
40	5	head	NN	O	B-NP	O
40	6	of	IN	O	B-PP	O
40	7	research	NN	O	B-NP	O
40	8	and	CC	O	I-NP	O
40	9	development	NN	O	I-NP	O
40	10	at	IN	O	B-PP	O
40	11	Genentech	NNP	O	B-NP	B-OrgCorp
40	12	COMMA	COMMA	O	O	O
40	13	immediately	RB	O	O	O
40	14	replaced	VBD	O	B-VP	O
40	15	Raab	NNP	O	B-NP	B-Peop
40	16	and	CC	O	O	O
40	17	is	VBZ	O	B-VP	O
40	18	credited	VBN	O	I-VP	O
40	19	with	IN	O	B-PP	O
40	20	creating	VBG	O	B-VP	O
40	21	the	DT	O	B-NP	O
40	22	company	NN	O	I-NP	B-OrgCorp
40	23	's	POS	O	B-NP	O
40	24	current	JJ	O	I-NP	O
40	25	product	NN	O	I-NP	O
40	26	pipeline	NN	O	I-NP	O
40	27	.	.	O	O	O

41	0	``	``	O	O	O
41	1	Since	IN	O	B-PP	O
41	2	1995	CD	O	B-NP	B-Date
41	3	we	PRP	O	B-NP	O
41	4	've	VBP	O	B-VP	O
41	5	been	VBN	O	I-VP	O
41	6	in	IN	O	B-PP	O
41	7	a	DT	O	B-NP	O
41	8	period	NN	O	I-NP	O
41	9	that	IN	O	B-NP	O
41	10	I	PRP	O	B-NP	O
41	11	would	MD	O	B-VP	O
41	12	call	VB	O	I-VP	O
41	13	a	DT	O	B-NP	O
41	14	reinvigoration	NN	O	I-NP	O
41	15	of	IN	O	B-PP	O
41	16	the	DT	O	B-NP	O
41	17	companyCOMMA	NN	O	I-NP	O
41	18	''	''	O	O	O
41	19	Lavigne	NNP	O	B-NP	B-Peop
41	20	said	VBD	O	B-VP	O
41	21	.	.	O	O	O

42	0	&	CC	O	O	O
42	1	QL	NNP	O	B-NP	O
42	2	;	:	O	O	O
42	3	-LBR-	-LBR-	O	O	O
42	4	STORY	NNP	O	B-NP	O
42	5	CAN	NNP	O	I-NP	O
42	6	END	NNP	O	I-NP	O
42	7	HERE	NNP	O	I-NP	O
42	8	.	.	O	O	O

43	0	OPTIONAL	NNP	O	O	B-Org
43	1	MATERIAL	NNP	O	O	I-Org
43	2	FOLLOWS.	NNP	O	O	I-Org
43	3	-RBR-	-RBR-	O	O	O
43	4	&	CC	O	O	O
43	5	QL	NNP	O	B-NP	O
43	6	;	:	O	O	O

44	0	&	CC	O	O	O
44	1	QL	NNP	O	B-NP	O
44	2	;	:	O	O	O

45	0	Chovav	NNP	O	O	O
45	1	of	IN	O	B-PP	O
45	2	Salomon	NNP	O	B-NP	O
45	3	Smith	NNP	O	I-NP	B-Peop
45	4	Barney	NNP	O	I-NP	I-Peop
45	5	put	VBD	O	B-VP	O
45	6	it	PRP	O	B-NP	O
45	7	more	RBR	O	O	O
45	8	bluntly	RB	O	O	O
45	9	:	:	O	O	O
45	10	``	``	O	O	O
45	11	Art	NNP	O	B-NP	O
45	12	Levinson	NNP	O	I-NP	B-Peop
45	13	is	VBZ	O	B-VP	O
45	14	probably	RB	O	O	O
45	15	the	DT	O	B-NP	O
45	16	best	JJS	O	I-NP	O
45	17	thing	NN	O	I-NP	O
45	18	that	DT	O	B-NP	O
45	19	happened	VBD	O	B-VP	O
45	20	to	TO	O	B-PP	O
45	21	GenentechCOMMA	NNP	O	B-NP	O
45	22	''	''	O	O	O
45	23	she	PRP	O	B-NP	O
45	24	said	VBD	O	B-VP	O
45	25	.	.	O	O	O

46	0	To	TO	O	B-VP	O
46	1	accomplish	VB	O	I-VP	O
46	2	its	PP$	O	B-NP	O
46	3	production	NN	O	I-NP	O
46	4	goals	NNS	O	I-NP	O
46	5	COMMA	COMMA	O	O	O
46	6	Genentech	NNP	O	B-NP	B-OrgCorp
46	7	has	VBZ	O	B-VP	O
46	8	been	VBN	O	I-VP	O
46	9	forging	VBG	O	I-VP	O
46	10	strategic	JJ	O	B-NP	O
46	11	alliances	NNS	O	I-NP	O
46	12	with	IN	O	B-PP	O
46	13	other	JJ	O	B-NP	O
46	14	biotech	JJ	O	I-NP	O
46	15	and	CC	O	I-NP	O
46	16	pharmaceutical	JJ	O	I-NP	B-Medical
46	17	outfits	NN	O	I-NP	O
46	18	.	.	O	O	O

47	0	That	DT	O	B-NP	O
47	1	way	NN	O	I-NP	O
47	2	COMMA	COMMA	O	O	O
47	3	development	NN	O	B-NP	O
47	4	costs	NNS	O	I-NP	O
47	5	are	VBP	O	B-VP	O
47	6	shared	VBN	O	I-VP	O
47	7	and	CC	O	O	O
47	8	products	NNS	O	B-NP	O
47	9	get	VBP	O	B-VP	O
47	10	to	TO	O	I-VP	O
47	11	market	VB	O	I-VP	O
47	12	faster	JJR	O	O	O
47	13	because	IN	O	O	O
47	14	two	CD	O	B-NP	B-Num
47	15	companies	NNS	O	I-NP	B-OrgCorp
47	16	are	VBP	O	B-VP	O
47	17	involved	VBN	O	I-VP	O
47	18	.	.	O	O	O

48	0	Genentech	NNP	O	B-NP	B-Peop
48	1	also	RB	O	O	O
48	2	hasn	NN	O	B-NP	O
48	3	't	NN	O	I-NP	O
48	4	cut	VBP	O	B-VP	O
48	5	back	NN	O	O	O
48	6	on	IN	O	B-PP	O
48	7	research	NN	O	B-NP	O
48	8	and	CC	O	I-NP	O
48	9	development	NN	O	I-NP	O
48	10	.	.	O	O	O

49	0	In	IN	O	B-PP	O
49	1	1995	CD	O	B-NP	B-Date
49	2	COMMA	COMMA	O	O	O
49	3	Genentech	NNP	O	B-NP	B-OrgCorp
49	4	spent	VBD	O	B-VP	O
49	5	$363	NN	O	B-NP	B-Money
49	6	million	CD	O	I-NP	B-Num
49	7	COMMA	COMMA	O	O	O
49	8	or	CC	O	O	O
49	9	40	CD	O	B-NP	B-NumPercent
49	10	percent	NN	O	I-NP	I-NumPercent
49	11	of	IN	O	B-PP	O
49	12	sales	NNS	O	B-NP	O
49	13	COMMA	COMMA	O	O	O
49	14	on	IN	O	B-PP	O
49	15	research	NN	O	B-NP	O
49	16	and	CC	O	I-NP	O
49	17	development	NN	O	I-NP	O
49	18	.	.	O	O	O

50	0	The	DT	O	B-NP	O
50	1	following	VBG	O	I-NP	O
50	2	two	CD	O	I-NP	B-Num
50	3	years	NNS	O	I-NP	B-Date
50	4	COMMA	COMMA	O	O	O
50	5	the	DT	O	B-NP	O
50	6	company	NN	O	I-NP	B-OrgCorp
50	7	spent	VBD	O	B-VP	O
50	8	$471	NN	O	B-NP	B-Money
50	9	million	CD	O	I-NP	B-Num
50	10	COMMA	COMMA	O	O	O
50	11	or	CC	O	O	O
50	12	about	IN	O	B-NP	O
50	13	50	CD	O	I-NP	B-NumPercent
50	14	percent	NN	O	I-NP	I-NumPercent
50	15	of	IN	O	B-PP	O
50	16	revenues	NNS	O	B-NP	O
50	17	.	.	O	O	O
